George W. Lloyd - 12 Jul 2021 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role
EVP, Investments & GC
Signature
/s/ Sean Weisberg, as Attorney-in-Fact for George W. Lloyd
Issuer symbol
RPRX
Transactions as of
12 Jul 2021
Net transactions value
-$972,456
Form type
4
Filing time
14 Jul 2021, 17:18:40 UTC
Previous filing
08 Jul 2021
Next filing
27 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPRX Class A Ordinary Shares Sale $4,204 -100 -0.01% $42.04 806,430 12 Jul 2021 By GWL 2014 G, LLC
transaction RPRX Class A Ordinary Shares Sale $212,890 -5,068 -0.84% $42.01 600,773 13 Jul 2021 By GWL 2013 NG, LLC F1
transaction RPRX Class A Ordinary Shares Sale $755,362 -17,981 -2.2% $42.01 788,449 13 Jul 2021 By GWL 2014 G, LLC F2
holding RPRX Class A Ordinary Shares 240,000 12 Jul 2021 By GWL 2020 G, LLC
holding RPRX Class A Ordinary Shares 3,000 12 Jul 2021 Direct
holding RPRX Class A Ordinary Shares 273,960 12 Jul 2021 By IRA
holding RPRX Class A Ordinary Shares 4,000 12 Jul 2021 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

All reported transactions were effected pursuant to 10b5-1 plans adopted by the reporting person on December 28, 2020.